GC Biopharma and Hanmi Pharm sign ₩634.7B technology export of Fabry disease drug to US's BioMarin, expanding K-pharma's reach
Predicted impact: Medium
₩634.7B license deal, about 38% of revenue, but already reported in earlier items this fortnight.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.